Zai Lab Ltd. Unsponsored ADR Stock

$43.03

3.94% yesterday

Nasdaq, Jun 12, 10:00 pm CET

ISIN

US98887Q1040

Symbol

ZLAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Zai Lab Ltd. Unsponsored ADR Stock price

$43.03

-25.97 37.64% 5Y

Nasdaq, Closing price Thu, Jun 12 2025

+1.63 3.94%

ISIN

US98887Q1040

Symbol

ZLAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$4.46b
Enterprise Value	$3.88b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	9.27
P/S ratio (TTM) P/S ratio	10.66
P/B ratio (TTM) P/B ratio	57.54
Revenue growth (TTM) Revenue growth	43.72%
Revenue (TTM) Revenue	$418.33m
EBIT (operating result TTM) EBIT	$-268.12m
Free Cash Flow (TTM) Free Cash Flow	$-238.84m
Cash position	$757.26m
EPS (TTM) EPS	$-0.25
P/E forward	negative
P/S forward	7.85
EV/Sales forward	6.82
Short interest	5.30%

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Get Started for Free Today

Zai Lab Ltd. Unsponsored ADR Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

14x Buy

88%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from Zai Lab Ltd. Unsponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	418 418	44% 44% 100%
- Direct Costs	152 152	41% 41% 36%
Gross Profit	266 266	45% 45% 64%
- Selling and Administrative Expenses	293 293	2% 2% 70%
- Research and Development Expense	241 241	12% 12% 58%
EBITDA	-256 -256	29% 29% -61%
- Depreciation and Amortization	12 12	31% 31% 3%
EBIT (Operating Income) EBIT	-268 -268	27% 27% -64%
Net Profit	-252 -252	26% 26% -60%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Zai Lab Ltd. Unsponsored ADR Stock News

Neutral

Business Wire

●

11 days ago

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating zocilurtatug pelitecan, or ZL-1310, the Company's potential first-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for patients with extensive-stage small cell lung cancer (ES-SCLC),...

Neutral

Business Wire

●

13 days ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in ...

Neutral

Business Wire

●

14 days ago

Zai Lab Announces Participation in Investor Conferences in June 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in June 2025: Jefferies Global Healthcare Conference Fireside Chat: Wednesday, June 4, 2025, 10:30 a.m. EST Webcast Link: https://wsw.com/webcast/jeff319/zlab/1845848 Location: New Yor...

More Zai Lab Ltd. Unsponsored ADR News

Company Profile

Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.

Head office	Cayman Islands
CEO	Ying Du
Employees	1,869
Founded	2014
Website	www.zailaboratory.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now